Home › Merck Statement Regarding CUBICIN (daptomycin for injection) Patent Litigation
 

Keywords :   


Merck Statement Regarding CUBICIN (daptomycin for injection) Patent Litigation

2015-11-12 17:49:00| Merck.com - Corporate News

Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, issued the following statement regarding the decision of the U.S. Court of Appeals for the Federal Circuit. The decision validated the patent for CUBICIN (daptomycin for injection) that expires on June 15, 2016, but invalidated four patents with expiration dates in 2019 and 2020. Language: English Contact: MerckMedia:Lainie Keller, 908-236-5036Steve Cragle, 908-740-1801orInvestors:Teri Loxam, 908-740-1986Justin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: statement patent litigation injection

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
01.06The Perils of Progress in the Search for New UV Filters
01.06This Interview Formality Jumpstarts Or Kills Your Chances Altogether
01.06Atlantic Tropical Weather Outlook
01.06Eastern North Pacific Tropical Weather Outlook
01.06You May Ask Yourself How Did We Get Here?
01.06Retinol Benefits With a Natural and Safe Alternative
01.06Tween Color Cosmetics Brand Talomi Puts a New Face on Beauty 
01.06How HCPA Racks Up Wins At State & Federal Levels
More »